Scholarlink

Purpose <p>Lipid nanoparticle (LNP)-based drug delivery systems have emerged as important nanomedicine platforms because of their favorable physicochemical properties, high biocompatibility, scalable manufacturing potential, and ability to efficiently encapsulate diverse therapeutic payloads. This review critically evaluates recent advances in LNP design, formulation engineering, therapeutic applications, and translational progress, with emphasis on how lipid composition and nanoparticle architecture influence biological performance and clinical utility.</p> Methods <p>A structured literature review was conducted using major scientific databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify relevant peer-reviewed articles, reviews, clinical studies, and regulatory reports related to LNP formulation, characterization, therapeutic applications, and clinical translation. Literature published mainly between 2015 and 2025 was prioritized, while selected earlier studies were included for essential mechanistic and historical context.</p> Results <p>Recent advances in ionizable lipid chemistry, helper lipid selection, PEG-lipid engineering, surface functionalization, and microfluidic manufacturing have significantly improved encapsulation efficiency, intracellular delivery, biodistribution control, and translational scalability of LNP systems. The reviewed evidence indicates that subtle changes in lipid composition and structural organization can strongly influence endosomal escape, cellular uptake, immune interactions, therapeutic efficacy, and safety. LNPs have shown broad therapeutic utility across oncology, infectious diseases, inflammatory disorders, neurological diseases, metabolic disorders, and genome-editing applications. However, challenges related to immune activation, off-target accumulation, formulation instability, large-scale manufacturing, and regulatory complexity continue to limit broader clinical implementation.</p> Conclusion <p>LNPs represent one of the most versatile and clinically advanced nanomedicine platforms for the delivery of nucleic acids and other therapeutic agents. Continued progress in rational lipid design, targeted delivery, scalable manufacturing, and regulatory standardization is expected to accelerate the development of safer and more effective next-generation LNP therapeutics.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lipid Nanoparticles Based Drug Delivery Systems: Design Innovations, Therapeutic Applications, and Translational Progress

  • 期刊论文

  • 发表日期：

    2026年7月1日

查看全文
  • Abdul Shadab,
  • Md. Faheem Haider,
  • Mohammad Abohassan

摘要

Purpose

Lipid nanoparticle (LNP)-based drug delivery systems have emerged as important nanomedicine platforms because of their favorable physicochemical properties, high biocompatibility, scalable manufacturing potential, and ability to efficiently encapsulate diverse therapeutic payloads. This review critically evaluates recent advances in LNP design, formulation engineering, therapeutic applications, and translational progress, with emphasis on how lipid composition and nanoparticle architecture influence biological performance and clinical utility.

Methods

A structured literature review was conducted using major scientific databases, including PubMed, Scopus, Web of Science, and Google Scholar, to identify relevant peer-reviewed articles, reviews, clinical studies, and regulatory reports related to LNP formulation, characterization, therapeutic applications, and clinical translation. Literature published mainly between 2015 and 2025 was prioritized, while selected earlier studies were included for essential mechanistic and historical context.

Results

Recent advances in ionizable lipid chemistry, helper lipid selection, PEG-lipid engineering, surface functionalization, and microfluidic manufacturing have significantly improved encapsulation efficiency, intracellular delivery, biodistribution control, and translational scalability of LNP systems. The reviewed evidence indicates that subtle changes in lipid composition and structural organization can strongly influence endosomal escape, cellular uptake, immune interactions, therapeutic efficacy, and safety. LNPs have shown broad therapeutic utility across oncology, infectious diseases, inflammatory disorders, neurological diseases, metabolic disorders, and genome-editing applications. However, challenges related to immune activation, off-target accumulation, formulation instability, large-scale manufacturing, and regulatory complexity continue to limit broader clinical implementation.

Conclusion

LNPs represent one of the most versatile and clinically advanced nanomedicine platforms for the delivery of nucleic acids and other therapeutic agents. Continued progress in rational lipid design, targeted delivery, scalable manufacturing, and regulatory standardization is expected to accelerate the development of safer and more effective next-generation LNP therapeutics.

Graphical Abstract